UPCC 22219 Dynamic Nuclear Polarization-MR Spectroscopic Imaging of Hepatocellular Carcinoma Metabolism to Predict Response Following Locoregional or Systemic Therapy

UPCC 22219 Dynamic Nuclear Polarization-MR Spectroscopic Imaging of Hepatocellular Carcinoma Metabolism to Predict Response Following Locoregional or Systemic Therapy
Enrolling By Invitation
18 years - 99 years
All
Phase 2
130 participants needed
1 Location

Brief description of study

The research study is being conducted to evaluate a new imaging technique for detecting the response of hepatocellular carcinoma (HCC) to locoregional or systemic therapy. Locoregional therapies or LRT are called Transarterial Chemoembolization or TACE, Transarterial Radioembolization or TARE and Microwave Ablation or MWA. Systemic therapies or ST are therapy drugs that spread throughout the body to treat cancer cells. They include chemotherapy, hormonal therapy, targeted drugs, and immunotherapy.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Hepatocellular Carcinoma
  • Age: 18 years - 99 years
  • Gender: All

Male or Female, Age 18 or older, at least one tumor meeting LI-RADS 5 criteria on imaging, and referred to undergo LRT or receive ST.

Updated on 09 Sep 2026. Study ID: 20-0011
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245

Study is selecting its participants from a population, or group of people, decided on by the researchers in advance.

Contact Abramson Cancer Center Navigator